Tom 5, Nr 2 (2020)
Artykuły przeglądowe / Review articles
Opublikowany online: 2020-04-10
Wyświetlenia strony
295
Wyświetlenia/pobrania artykułu
220
Adjuvant radioiodine treatment in patients with thyroid cancer – current recommendations
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2020;5(2):82-85.
Streszczenie
Radioactive iodine therapy (RAI) has been used in patients with differentiated thyroid cancers (DTC) for many decades.
However, many changes in thyroid cancer treatment have been introduced for the last decade worldwide, mainly a
tendency to deescalate both surgical and adjuvant treatment has been observed. This work summarizes current Polish
guidelines for adjuvant radioiodine therapy compared to American Thyroid Association recommendations.
Słowa kluczowe: radioiodine treatmentthyroid cancer
Referencje
- Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018; 91(1091): 20180136.
- Haugen BR, Haugen BR, Alexander EK, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
- Treglia G, Aktolun C, Chiti A, et al. EANM and the EANM Thyroid Committee. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2016; 43(8): 1486–1490.
- Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. Endokrynol Pol. 2018; 69(1): 34–74.
- Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019; 29(1): 7–26.
- Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. The Lancet Diabetes & Endocrinology. 2018; 6(8): 618–626.
- Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7(1): 44–51.
